Doctors call Moderna, Merck cancer vaccine data a major advancement - despite Wall Street reaction
Article excerpt
In this article Leaked confidential data. A major stock sell-off. Beneath the chaos surrounding Moderna and Merck 's latest data on their personalized cancer vaccine, oncologists see something else: an important milestone in melanoma treatment. The companies on Thursday released detailed results from a Phase 3 trial on their mRNA-based shot after partial data leaked on social media platforms earlier that day. The vaccine, known as intismeran autogene, reduced the risk of melanoma recurrence or death by 42% when given alongside Merck's immunotherapy Keytruda, compared with Keytruda alone. The combination also reduced the risk of cancer spreading to distant parts of the body or death by 38%, compared with just the immunotherapy, according to the trial on roughly 1,100 patients whose tumors were removed by surgery. The stock market's reaction contrasted with the assessment of six melanoma specialists, who told CNBC the results represent a clinically meaningful advance that could eventually become a standard of care for patients who undergo surgery first and have not received immunotherapy before their operation. "This has the potential to be a major breakthrough in melanoma treatment and also cancer immunotherapy in general that will open the door to greater outcomes for patients," said Dr. Sekwon Jang, a melanoma specialist at Inova Schar Cancer and principal investigator at...
Keep reading with a free account
The rest of this article, and every signal for Moderna, is in your free account.
Extracted from this sentence
In an interview ahead of the results, Moderna CEO Stéphane Bancel said the company is finishing a filing with regulators as it aims to get the drug fully approved next year.
